Abstract
During the past 20 years, the world pharmaceutical industry has experienced a dramatic increase in R&D intensity. We apply and extend a model developed by Grabowski and Vernon (2000, Journal of Evolutionary Economics, 10, 201–215) with a pooled data sample of the 15 publicly listed Japanese drug firms for the period 1987–1998. As in the original study, we find expected returns to be an important determinant of R&D spending in the Japanese drug industry, albeit considerably smaller than in the U.S., which is particularly obvious in the case of returns from newly introduced drugs. However, our results are sensitive to econometric model specification, in particular to controlling for serial correlation and to a dynamic specification of the baseline model. Likewise, estimates on financial constraints are sensitive to model specification, indicating that Japanese drug firms face small or no financial constraints. Our results are consistent with the general literature on R&D investment behaviour, yet raise some methodological questions with regard to the original study.
Similar content being viewed by others
References
Z. J. Acs D. B. Audretsch (1991) Innovation and Technological Change: An International Comparison Basil Blackwell Oxford
G. A. Akerlof (1970) ArticleTitle‘The Market for “Lemons”: Quality, Uncertainty and the Market Mechanism’ Quarterly Journal of Economics 84 488–500
M. Arellano S. R. Bond (1991) ArticleTitle‘Some Tests of Specification for Panel Data: Monte Carlo Evidence and An Application to Employment Equations’ Review of Economic Studies 58 277–297
B. H. Baltagi P. X. Wu (1999) ArticleTitle‘Unequally Spaced Panel Data Regressions with AR(1) Disturbances’ Econometric Theory 15 814–823 Occurrence Handle10.1017/S0266466699156020
R. W. Blundell S. R. Bond (1998) ArticleTitle‘Initial Conditions and Moment Restrictions in Dynamic Panel Data Models’ Journal of Econometrics 87 115–143 Occurrence Handle10.1016/S0304-4076(98)00009-8
Bond S., Harhoff D., and J. Van Reenen (2003) Investment, R&D, and Financial Constraints in Britain and Germany. Centre for Economic Performance, LSE, CEP Discussion Paper, 0595.
S. R. Bond (2002) ArticleTitle‘Dynamic Panel Data Models: A Guide to Micro Data Methods and Practice’ Portuguese Economic Journal 1 141–162 Occurrence Handle10.1007/s10258-002-0009-9
W. M. Cohen (1995) ‘Empirical Studies of Innovative Activity’ P. Stoneman (Eds) Handbook of the Economics of Innovation and Technological Change Blackwell Oxford 182–264
W. M. Cohen D. Levinthal (1990) ArticleTitle‘Absorptive Capacity: A New Perspective on Learning and Innovation’ Administrative Science Quarterly 35 128–152
W. M. Cohen D. Levinthal (1989) ArticleTitle‘Innovation and Learning: The Two Faces of R&D’ Economic Journal 99 569–596
H. G. Grabowski J. M. Vernon (2000) ArticleTitle‘The Determinants of Pharmaceutical Research and Development Expenditures’ Journal of Evolutionary Economics 10 201–215 Occurrence Handle10.1007/s001910050012
H. G. Grabowski J. M. Vernon (1994) ArticleTitle‘Return to R&D in New Drug Introductions in the 80’s’ Journal of Health Economics 13 383–406 Occurrence Handle10.1016/0167-6296(94)90010-8
Griliches Z., and J. Mairesse (1990) ‘R&D and Productivity Growth: Comparing Japanese and US Manufacturing Firms’, in C. Hulten (ed.), Productivity Growth in Japan and the United States. Chicago, pp. 317–348.
K. Gugler D. C. Mueller B. B. Yurtoglu (2003) ArticleTitle‘Marginal q, Tobin’s q, Cash Flow and Investment’ Southern Economic Journal 70 512–531
B. H. Hall (2002) ArticleTitle‘The Financing of Research and Development’ Oxford Review of Economic Policy 18 35–51
Hall B. H. (1992) Investment and Research and Development at the Firm Level: Does the Source of Financing Matter. NBER Working paper, no. 4096, NBER: Cambridge, MA.
B. H. Hall J. Mairesse L. Branstetter B. Crépon (1999) ‘Does Cash Flow Cause Investment and R&D: An Exploration Using Panel Data for French, Japanese and United State Firms in the Scientific Sector’ D. Audretsch R.R. Thurik (Eds) Innovation, Industry Evolution and Employment Cambridge University Press Cambridge
R. M. Henderson I. Cockburn (1996) ArticleTitle‘Scale, Scope and Spillovers: The determinants of Research Productivity in Drug Discovery’ RAND Journal of Economics 27 32–59
A. Hisashige (1997) ArticleTitle‘Healthcare Technology Assessment and the Challenge to Pharmaeconomics in Japan’ PharmacoEconomics 11 319–333
T. Hoshi A. K. Kashyap (2001) Corporate Financing and Governance in Japan MIT Press Cambridge, MA
T. Hoshi A. Kashyap D. Scharfstein (1991) ArticleTitle‘Corporate Structure, Liquidity and Investment: Evidence from Japanese Panel Data’ Quarterly Journal of Economics 100 33–60
R. G. Hubbard (1998) ArticleTitle‘Capital-Market Imperfections and Investment’ Journal of Economic Literature 26 193–225
C. Huttin (1995) ArticleTitle‘The Japanese Drug Price Policy: A New Dynamic on Price Competition’ Journal of Research in Pharmaceutical Economics 4 21–34
IMS HEALTH (2003) IMS World Review 2003. Fairfield, CT.
Koseisho [Ministry of Health and Welfare] (1996) Kazoku to shakai hosho- kazoku no shakai-teki shien no tame ni [Family and Social Insurance]. Tokyo.
M. McLellan (1997) ArticleTitle‘A Turning Point in Japanese Sales Promotion’ Scrip Magazine 10 25–27
Miarka T. (1999) ‘The Recent Economic Role of Bank-firm Relationships in Japan.’ WZB Discussion Paper, FS IV 99–36.
Morgan Stanley Dean Witter (1998) Japan Investment Research: Japan Pharmaceuticals. Tokyo.
B. Mulkay B. H. Hall J. Mairesse (2001) ‘Investment and R&D in France and in the United State’ D. Bundesbank (Eds) Investing Today for the World of Tomorrow Springer Berlin, Heidelberg and New York
InstitutionalAuthorNameOECD (2001) Science, Technology and Industry Scoreboard 2001 OECD Paris
A. J. Oliver N. Ikegami S. Ikeda (1997) ArticleTitle‘Japan’s Aging Population – Implications for Healthcare’ PharmacoEconomics 11 306–318
PhRMA (2003) Industry Profile. Washington, D.C.
PhRMA (1999) Industry Profile. Washington, D.C.
M. R. Reich (1990) ArticleTitle‘Why the Japanese don’t Export More Pharmaceuticals: Health Policy as Industrial Policy’ California Management Review 32 124–150
F. M. Scherer D. Harhoff J. Kukies (2000) ArticleTitle‘Uncertainty and the Size Distribution of Rewards from Innovation’ Journal of Evolutionary Economics 10 175–200 Occurrence Handle10.1007/s001910050011
M. Sharp P. Patel (1997) ‘Europe’s Pharmaceutical Industry: an Innovation Profile’ A. Arundel R. Garrelfs (Eds) Innovation Measurement and Policies European Commission Luxembourg
Silverberg G., and B. Verspagen (2005) ‘The Size Distribution of Innovations Revisited: an Application of Extreme Value Statistics to Citation and Value Measures of Patent Significance’, Journal of Econometrics, (forthcoming).
L. G. Thomas (2001) The Japanese Pharmaceutical Industry: The New Drug Law and the Failure of Industrial Policy Edward Elgar Cheltenham, UK and Northampton, MA, US
A. Tylecote (1994) ‘Financial Systems and Innovation’ M. Dodgson R. Rothwell (Eds) The Handbook of Industrial Innovation Edward Elgar Aldershot, UK and Brookfield, US 259–267
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mahlich, J.C., Roediger-Schluga, T. The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan. Rev Ind Organ 28, 145–164 (2006). https://doi.org/10.1007/s11151-006-0010-z
Issue Date:
DOI: https://doi.org/10.1007/s11151-006-0010-z